CSL to buy Talecris Biotherapeutics for $3.1 billion

Australian plasma giant CSL will tap several sources to pay for the purchase of the US company, including a $1.5 billion share placement.

To continue reading, please login or register for free

Print Edition

FinanceAsia Print Edition

CONFERENCES